Increased secretion of IL-8 and IL-6 promotes the expression of BC resistance protein (BRCP) by activating the AKT and STAT3 signaling pathways, respectively, which induce doxorubicin treatment resistance by accelerating efflux from BC cells. This evidence concerns the gene AKT1 and breast cancer.